Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Alimera Sciences price target lowered to $15 from $24 at B. Riley FBR » 08:36
04/07/20
04/07
08:36
04/07/20
08:36
ALIM

Alimera Sciences

$4.00 /

+0.59 (+17.30%)

B. Riley FBR analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a week ago
Hot Stocks
Alimera Sciences announces data available for 11th annual COPHy congress » 08:25
03/25/20
03/25
08:25
03/25/20
08:25
ALIM

Alimera Sciences

$3.87 /

+0.77 (+24.84%)

Alimera Sciences…

Alimera Sciences announces that nine posters on ILUVIEN 0.19 mg for intravitreal injection will be available online during and after the 11th Annual Congress on Controversies in Ophthalmology conference beginning March 27, 2020, a yearly congress held virtually this year due to precautions around the coronavirus. Highlighted posters include: "Benefit of Early ILUVIEN Treatment - Chronicity of Diabetic Macular Edema as Predictor of Visual and Anatomical Outcomes" to be presented by J. Heitor Marques, Department of Ophthalmology, Centro Hospitalar Universitario do Porto, Portugal URL "Fluocinolone Acetonide Intravitreal Implant Outcomes on the Prevention of Relapse in Recurrent Birdshot Retinochoroidopathy: 3-Year Outcomes" to be presented by M. Cordeiro and M. Guedes Department of Ophthalmology, Centro Hospitalar de Lisboa Ocidental, Portugal URL

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
Hot Stocks
Alimera Sciences regains compliance with the Nasdaq listing rules » 14:10
03/06/20
03/06
14:10
03/06/20
14:10
ALIM

Alimera Sciences

$6.50 /

-0.16 (-2.40%)

In a regulatory filing,…

In a regulatory filing, Alimera Sciences reported that on March 6, the company received a letter from Nasdaq informing that it has regained compliance with the Nasdaq Listing Rules based on compliance with the total assets / total revenue listing standard. "That standard requires a listed company's revenue and total assets to exceed $50 million in each case for the most recently completed fiscal year (and meet certain other requirements that we also met). Our audited consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, which we filed with the SEC on March 2, 2020, reflect that we met this standard as of December 31, 2019, the end of our most recent fiscal year," the company stated.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Fly Intel: After Hours Movers » 19:03
02/26/20
02/26
19:03
02/26/20
19:03
SPT

Sprout Social

$17.70 /

-1.11 (-5.90%)

, TDOC

Teladoc

$116.89 /

-1.55 (-1.31%)

, AKRX

Akorn

$1.29 /

-0.04 (-3.02%)

, ALIM

Alimera Sciences

$6.38 /

-0.06 (-0.93%)

, ETSY

Etsy

$50.64 /

+0.73 (+1.46%)

, ESTC

Elastic

$63.78 /

-2.235 (-3.39%)

, DDD

3D Systems

$10.24 /

-0.355 (-3.35%)

, BOX

Box

$14.98 /

-0.075 (-0.50%)

, NTRA

Natera

$34.76 /

-0.2 (-0.57%)

, CPE

Callon Petroleum

$2.21 /

-0.14 (-5.96%)

, UPWK

Upwork

$8.13 /

-0.19 (-2.28%)

, SQ

Square

$76.63 /

-0.38 (-0.49%)

, CLW

Clearwater Paper

$26.98 /

+0.71 (+2.70%)

, RUBI

Rubicon Project

$11.03 /

-0.6 (-5.16%)

, NDLS

Noodles & Company

$7.90 /

-0.35 (-4.24%)

, OPK

Opko Health

$1.39 /

-0.005 (-0.36%)

, ARNA

Arena Pharmaceuticals

$46.98 /

-0.93 (-1.94%)

, ACAD

Acadia

$40.30 /

-0.37 (-0.91%)

, SWX

Southwest Gas

$71.84 /

-2.02 (-2.73%)

, CLGX

CoreLogic

$48.39 /

+ (+0.00%)

, QGEN

Qiagen

$35.08 /

+0.09 (+0.26%)

, GILD

Gilead

$74.70 /

+4.57 (+6.52%)

, CLR

Continental Resources

$20.79 /

-1.125 (-5.13%)

, NTNX

Nutanix

$32.65 /

-2.08 (-5.99%)

, TPC

Tutor Perini

$11.99 /

+0.46 (+3.99%)

, QEP

QEP Resources

$2.16 /

-0.105 (-4.64%)

, MED

Medifast

$94.05 /

-1.09 (-1.15%)

, CVNA

Carvana

$101.66 /

-2.535 (-2.43%)

, LHCG

LHC Group

$150.40 /

+1.81 (+1.22%)

, FRGI

Fiesta Restaurant

$9.07 /

-0.91 (-9.12%)

, CCI

Crown Castle

$162.74 /

-0.33 (-0.20%)

, PTLA

Portola Pharmaceuticals

$12.51 /

-0.13 (-1.03%)

, PDCE

PDC Energy

$18.48 /

-1 (-5.13%)

, ANSS

Ansys

$273.00 /

+6.64 (+2.49%)

, SILK

Silk Road Medical

$45.25 /

-1.29 (-2.77%)

, RGNX

Regenxbio

$47.50 /

+0.13 (+0.27%)

, LB

L Brands

$22.77 /

-0.76 (-3.23%)

, NTES

NetEase

$345.55 /

+7.47 (+2.21%)

, BKNG

Booking Holdings

$1,683.38 /

-44.63 (-2.58%)

, MSFT

Microsoft

$170.20 /

+2.14 (+1.27%)

UP AFTER EARNINGS: Sprout…

UP AFTER EARNINGS: Sprout Social (SPT) up 18.6%... Teladoc (TDOC) up 17.2%... Akorn (AKRX) down 12.7%... Alimera Sciences (ALIM) up 11.5%... Etsy (ETSY) up 10.6%... Elastic (ESTC) up 10.5%... 3D Systems (DDD) up 9.2%... Box Inc (BOX) up 8.8%... Natera (NTRA) up 8.7%... Callon Petroleum (CPE) up 8.1%... Upwork (UPWK) up 8.0%... Square (SQ) up 7.4%... Clearwater Paper (CLW) up 5.6%... Rubicon Project (RUBI) up 5.5%... Noodles & Co (NDLS) up 5.4%... Opko Health (OPK) up 5.1%... Arena Pharma (ARNA) up 4.5%... Acadia Pharma (ACAD) up 4.1%... Southwest Gas (SWX) up 4.0%... Corelogic (CLGX) up 2.1%. ALSO HIGHER: Qiagen (QGEN) up 3.3% after announcing shipments of coronavirus test kits... Gilead (GILD) up 3.0% after initiating two phase 3 studies of antiviral Remdesivir in coronavirus. DOWN AFTER EARNINGS: Continental Resources (CLR) down 17.0%... Nutanix (NTNX) down 16.0%... Tutor Perini (TPC) down 15.8%... QEP Resources (QEP) down 14.8%... Medifast (MED) down 14.3%... Carvana (CVNA) down 10.7%... LHC Group (LHCG) down 6.9%... Fiesta Restaurant (FRGI) down 6.6%... Crown Castle (CCI) down 5.7%... Portola Pharma (PTLA) down 5.2%... PDC Energy (PDCE) down 5.0%... Ansys (ANSS) down 3.8%... Silk Road Medical (SILK) down 2.5%... Regenexbio (RGNX) down 2.3%... L Brands (LB) down 2.1%... NetEase (NTES) down 1.7%... Booking Holdings (BKNG) down 0.5%. ALSO LOWER: Microsoft (MSFT) down 1.4% after saying will not meet Q3 guidance in More Personal Computing segment. Movers as of 18:30ET.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Alimera Sciences reports Q4 EPS 8c, consensus (45c) » 16:26
02/26/20
02/26
16:26
02/26/20
16:26
ALIM

Alimera Sciences

$6.38 /

-0.06 (-0.93%)

Reports Q4 revenue…

Reports Q4 revenue $17.3M, consensus $14.27M. "I am extremely proud to report record revenue for Alimera for both the full year of 2019 and the recently completed fourth quarter. Our international business exceeded our expectations with overall revenue improving 49% year over year, driven by organic growth, our expansion into France, and the launch of the ILUVIEN(R) indication for uveitis in Germany and the United Kingdom in the second half of the year." said Rick Eiswirth, Alimera's President and Chief Executive Officer. "In the U.S. market, we closed out the year with record quarterly end user demand for ILUVIEN, a 14% increase over the fourth quarter of last year. We are also pleased to have reached a significant milestone, having achieved positive adjusted EBITDA for a full year for the first time in the history of the company." Basic and diluted net loss per share for 2019 was $(2.19) compared to basic net income per share for 2018 of $3.74 and diluted net income per share for 2018 of $3.71. Net income for 2018 was attributable to the gain on the extinguishment of Alimera's Series B Convertible Preferred Stock resulting from its exchange in September 2018 for Series C Convertible Preferred Stock.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Alimera Sciences accesses $2.5M under solar debt agreement » 08:20
02/24/20
02/24
08:20
02/24/20
08:20
ALIM

Alimera Sciences

$6.71 /

+ (+0.00%)

Alimera Sciences…

Alimera Sciences announced that it has drawn down the remaining $2.5M under the $45M term loan agreement with its current lenders, investment affiliates managed by Solar Capital Partners, LLC. Under the terms of the agreement, Alimera had the option to draw down an additional $2.5M if it achieved $30M in revenue for any trailing six-month period ending on or before November 30, 2020. The $2.5M loan brings the total Alimera borrowings under the agreement to the maximum $45M available.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
B. Riley FBR highlights six Specialty Pharma stocks for 2020 » 09:00
01/08/20
01/08
09:00
01/08/20
09:00
CYRX

Cryoport

$17.13 /

-0.06 (-0.35%)

, HROW

Harrow Health

$6.79 /

-0.165 (-2.37%)

, ALIM

Alimera Sciences

$6.73 /

-1.03 (-13.27%)

, CTSO

CytoSorbents

$3.76 /

-0.02 (-0.53%)

, IIN

IntriCon

$17.91 /

-0.2 (-1.10%)

, OPRX

OptimizeRx

$9.95 /

-0.06 (-0.60%)

B. Riley FBR analyst…

B. Riley FBR analyst Andrew D'Silva spotlights six names in the Specialty Pharmaceuticals space that he expects to outperform in 2020: Cryoport (CYRX), Harrow Health (HROW), Alimera Sciences (ALIM), CytoSorbents (CTSO), IntriCon (IIN) and OptimizeRx (OPRX). Each company either exited 2019 on a strong footing, where momentum is poised to carry over into 2020, or has fallen out of favor, but execution will result in a reversal, D'Silva tells investors in a research note.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a quarter ago
Hot Stocks
Alimera Sciences refinances debt facility with Solar Capital » 08:14
01/06/20
01/06
08:14
01/06/20
08:14
ALIM

Alimera Sciences

$7.95 /

+0.25 (+3.25%)

Alimera Sciences…

Alimera Sciences announced that it refinanced its debt facility by entering into a new $45M term loan agreement with its current lenders, investment affiliates managed by Solar Capital Partners, LLC, on December 31, 2019. The amount of the new funding includes an initial tranche of $42.5M used to repay the current facility, including principal, prepayment fees and accrued interest, and another $2.5M tranche that will be available if Alimera achieves $30M in revenue for any trailing six-month period ending on or before November 30, 2020. The new loan agreement has a term of 54 months to July 1, 2024, with monthly interest-only payments to January 1, 2023, when principal amortization begins. The interest-only period may be extended an additional six months if Alimera achieves $34.5M in revenue for any trailing six-month period ending on or before June 30, 2022.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Evercore ISI to hold a conference » 04:55
12/05/19
12/05
04:55
12/05/19
04:55
MTEM

Molecular Templates

$12.73 /

+0.81 (+6.80%)

, ALNA

Allena Pharmaceuticals

$2.31 /

+0.01 (+0.43%)

, MDGL

Madrigal Pharmaceuticals

$116.14 /

+2.44 (+2.15%)

, PHG

Philips

$46.39 /

+0.35 (+0.76%)

, QURE

uniQure

$65.39 /

+1.52 (+2.38%)

, MBIO

Mustang Bio

$3.89 /

+0.5 (+14.75%)

, SEEL

Seelos Therapeutics

$0.95 /

+0.0863 (+10.03%)

, CYAD

Celyad

$12.71 /

+0.56 (+4.61%)

, PFNX

Pfenex

$10.86 /

+0.34 (+3.23%)

, STRO

Sutro Biopharma

$11.00 /

-0.16 (-1.43%)

, AXNX

Axonics

$24.13 /

+0.56 (+2.38%)

, NBSE

NeuBase Therapeutics

$6.93 /

+0.05 (+0.73%)

, ZBH

Zimmer Biomet

$148.35 /

+4.93 (+3.44%)

, ALIM

Alimera Sciences

$7.16 /

+0.41 (+6.07%)

, INSM

Insmed

$23.36 /

+0.4 (+1.74%)

, ADMS

Adamas Pharmaceuticals

$6.40 /

-0.12 (-1.84%)

, AXGT

Axovant

$5.20 /

+0.08 (+1.56%)

, BCEL

Atreca

$13.00 /

-0.285 (-2.15%)

, MYOV

Myovant Sciences

$17.30 /

-1.26 (-6.79%)

, PIRS

Pieris Pharmaceuticals

$3.93 /

+0.03 (+0.77%)

, MYL

Mylan

$18.89 /

+0.365 (+1.97%)

, RCKT

Rocket Pharmaceuticals

$19.22 /

+0.88 (+4.80%)

, CBAY

CymaBay

$1.66 /

-0.01 (-0.60%)

, NBIX

Neurocrine

$118.67 /

+1.08 (+0.92%)

, TCDA

Tricida

$39.62 /

+0.09 (+0.23%)

, NTLA

Intellia Therapeutics

$17.67 /

+0.59 (+3.45%)

, ALKS

Alkermes

$21.24 /

+0.98 (+4.84%)

HealthCONx Conference…

HealthCONx Conference 2019 will be held in Boston on December 3-5.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Evercore ISI to hold a conference » 04:55
12/04/19
12/04
04:55
12/04/19
04:55
MTEM

Molecular Templates

$11.92 /

+0.24 (+2.05%)

, ALNA

Allena Pharmaceuticals

$2.30 /

-0.12 (-4.96%)

, MDGL

Madrigal Pharmaceuticals

$113.70 /

-0.66 (-0.58%)

, PHG

Philips

$46.04 /

+0.14 (+0.31%)

, QURE

uniQure

$63.87 /

+9.06 (+16.53%)

, MBIO

Mustang Bio

$3.39 /

+0.12 (+3.67%)

, SEEL

Seelos Therapeutics

$0.86 /

-0.041 (-4.55%)

, CYAD

Celyad

$12.15 /

+0.55 (+4.74%)

, PFNX

Pfenex

$10.52 /

+0.525 (+5.25%)

, STRO

Sutro Biopharma

$11.16 /

-0.09 (-0.80%)

, AXNX

Axonics

$23.57 /

+0.36 (+1.55%)

, NBSE

NeuBase Therapeutics

$6.88 /

-0.48 (-6.52%)

, ZBH

Zimmer Biomet

$143.42 /

-1.05 (-0.73%)

, ALIM

Alimera Sciences

$6.75 /

-0.02 (-0.30%)

, INSM

Insmed

$22.96 /

-0.11 (-0.48%)

, ADMS

Adamas Pharmaceuticals

$6.52 /

+0.37 (+6.02%)

, AXGT

Axovant

$5.12 /

-0.19 (-3.58%)

, BCEL

Atreca

$13.29 /

+3.185 (+31.53%)

, MYOV

Myovant Sciences

$18.56 /

-0.62 (-3.23%)

, PIRS

Pieris Pharmaceuticals

$3.90 /

-0.24 (-5.80%)

, MYL

Mylan

$18.53 /

-0.145 (-0.78%)

, RCKT

Rocket Pharmaceuticals

$18.34 /

+0.38 (+2.12%)

, CBAY

CymaBay

$1.67 /

+0.05 (+3.09%)

, NBIX

Neurocrine

$117.59 /

+0.77 (+0.66%)

, TCDA

Tricida

$39.53 /

-0.5 (-1.25%)

, NTLA

Intellia Therapeutics

$17.08 /

+0.03 (+0.18%)

, ALKS

Alkermes

$20.26 /

-0.29 (-1.41%)

HealthCONx Conference…

HealthCONx Conference 2019 will be held in Boston on December 3-5.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.